Fundz

Fundz Deep Dive

Everything you need to win Jennifer Kirk — in one platform.

Who to reach, what to say, and why now on Jennifer Kirk — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Jennifer Kirk — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Exubrion Therapeutics Appoints Jennifer Kirk As Chief Executive Officer

PRIVATEMar 18, 2025•about 1 year ago

Position

Chief Executive Officer

Company

Exubrion Therapeutics

Jennifer Kirk
BufordBiotechnologyHealth CareTherapeutics

Description

Exubrion Therapeutics announced the appointment of Jennifer Kirk to the company's Board of Directors and as the Chief Executive Officer effective May 3, 2025. Jennifer Kirk brings more than 28 years of leadership and business transformation experience, including a successful tenure at Medtronic, positioning her uniquely to lead Exubrion Therapeutics into the next phase of growth.

Company Information

Company

Exubrion Therapeutics

Location

Buford, Georgia, United States

About

Exubrion Therapeutics is the developer of Synovetin OA, a breakthrough injectable treatment that provides long-lasting relief for dogs suffering from chronic osteoarthritis. Utilizing proprietary radiotherapeutic technology, Synovetin OA offers targeted, localized therapy to reduce joint inflammation and pain, often providing up to a full year of improved mobility and quality of life with a single treatment.

Predictive Intelligence
Strategic

ML-powered predictions for Exubrion Therapeutics's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.